NEW YORK, August 7, 2026, 08:11 EDT — U.S. regular trading remained closed as premarket activity continued.
- Oklo’s Groves test reactor became critical in under a year following initial construction work. It was the fifth advanced reactor approved by the DOE to reach criticality this summer.
- Revenue for the second quarter reached $1.21 million. The net loss increased to $48.54 million, and cash plus marketable securities at the end of June stood at $3.01 billion.
- Based on Thursday’s closing price of $42.19, Oklo’s market capitalization stood at $7.19 billion. This puts $4.18 billion above its documented cash and securities.
Oklo’s reactor has achieved a milestone that addresses a specific execution risk. The firm constructed and activated a low-power test reactor in a short timeframe. However, commercial power production and cost efficiency at scale remain unproven.
This difference is now the key factor moving the stock. Based on Thursday’s valuation and the June balance sheet, $4.18 billion is reflected above cash and securities. The market is factoring in licensing developments, construction performance, and future revenue potential.
Groves successfully initiated a controlled, self-sustaining chain reaction at a low power level. According to the Department of Energy, the event took place on August 5 in Lockhart, Texas. This marks the fifth DOE-authorized milestone of its kind this summer.
Oklo handled construction, procurement, fuel and operations internally, Chief Executive Jacob DeWitte described the achievement as “an incredible milestone for our team.” Oklo
| Investor test | What Groves demonstrated | What remains unproved |
|---|---|---|
| Construction speed | Reached criticality less than a year after breaking ground | Consistently achieving schedules for larger-scale commercial facilities |
| Reactor operation | Managed a controlled chain reaction at minimal power | Commercial-scale performance, reliability and upkeep track record |
| Regulatory progress | Received Department of Energy clearance under pilot scheme | Nuclear Regulatory Commission greenlight for full commercial rollout |
| Economics | Learnings from procurement, workforce and initial commissioning | Facility expenses, agreed sale rates, profit and investor returns |
Groves is intended for future commercial isotope output, not for generating electricity as Aurora does. While lessons from its operation could benefit both ventures, each has a distinct revenue model.
DOE efforts may also aid with a subsequent NRC application, but do not serve as a substitute for commercial licensing. Under the suggested regulatory bridge, developers are required to demonstrate that DOE assessments meet NRC standards and cover any subsequent design modifications.
Friday’s filing highlighted the expense involved in accelerating execution. Revenue totaled $1.21 million, but net loss nearly doubled. Research expenses saw an increase of more than three times compared to the same quarter last year.
| Q2 metric | 2026 | 2025 | Change |
|---|---|---|---|
| Reported revenue | $1.21 million | $0 | Not comparable |
| Net loss | $48.54 million | $24.69 million | 96.6% larger |
| Research and development | $39.47 million | $11.47 million | 244.2% more |
| General and administrative | $34.21 million | $16.55 million | 106.7% more |
| Loss per share | $0.28 | $0.18 | $0.10 increase |
Oklo reported operating cash outflows of $65.46 million for the first half. Capital expenditures totaled approximately $126.9 million. The company stated that at-the-market equity offerings during the first half generated around $1.9 billion, boosting liquidity and expanding the equity base.
| Valuation bridge | $ billions |
|---|---|
| Market cap at close on August 6 | 7.186 |
| Cash and cash equivalents as of June 30 | 1.645 |
| Marketable debt securities as of June 30 | 1.362 |
| Total cash and marketable securities | 3.006 |
| Market capitalization excluding cash and securities | 4.180 |
| Cash and securities share of total market value | 41.8% |
The bridge has an intentionally straightforward design. It does not represent enterprise value. Liabilities, noncash assets, and future project commitments are omitted. It highlights only the equity value that remains after accounting for reported cash and securities.
Oklo’s market valuation surpassed that of NuScale Power NYSE:SMR by over twofold. The figure was nearly eight times higher compared to Nano Nuclear Energy NASDAQ:NNE. BWX Technologies NYSE:BWXT continued to hold a greater market cap and posted positive trailing earnings.
| Public nuclear company | Price before Friday’s open | Market value | Trailing EPS |
|---|---|---|---|
| Oklo NYSE:OKLO | $42.19 | $7.19 billion | -$0.84 |
| NuScale Power NYSE:SMR | $9.47 | $3.45 billion | -$2.20 |
| Nano Nuclear Energy NASDAQ:NNE | $17.61 | $0.91 billion | -$0.71 |
| BWX Technologies NYSE:BWXT | $166.70 | $15.34 billion | $3.87 |
The comparison is not exact, as reactor designs, fuel strategies and business models vary. Nevertheless, it highlights the degree of execution credit already factored into Oklo’s valuation.
Opinions on Wall Street are split. MarketBeat’s 23-analyst panel issued a “Moderate Buy” recommendation with an average price target of $88. The most recent action was Barclays PLC LON:BARC lowering its target on July 22. MarketBeat
| Firm and analyst | Date | Recommendation | Price-target action |
|---|---|---|---|
| 23-analyst consensus | Current | Moderate Buy | $88 average; $55–$130 range |
| Barclays PLC LON:BARC, Christine Cho | July 22 | Overweight | Reduced to $76 from $82 |
| Truist Financial NYSE:TFC, Christopher Souther | July 13 | Hold | Started at $55 |
| Guggenheim Securities, Joseph Osha | June 25 | Neutral | Began coverage without a target |
| UBS Group NYSE:UBS, Jon Windham | June 11 | Neutral | Lowered to $55 from $60 |
The recommendations were issued before both Groves criticality and the outcome on Friday. By 07:56 EDT, no updated broker action was listed in the referenced feed.
Risks: Groves might not significantly reduce NRC review times to compensate for risks in licensing, fuel, and construction. Additional financing will be needed for commercial plants. Issuing more shares may dilute existing holdings, and positive test results do not guarantee strong margins.
The upcoming evaluation focuses on commercial conversion. Investors are watching for updates on NRC developments, solid customer economics, and consistent plant timelines. Oklo has arranged its quarterly webcast for 08:30 EDT, following the publication of this article. (
Related articles: NYSE:OKLO
